2,474 results on '"Hereditary Cancer"'
Search Results
2. Previvors Recharge: A Resilience Program for Cancer Previvors (PreCharge)
- Author
-
Kerry E. Evers, Co-President and CEO, Principal Investigator
- Published
- 2024
3. Evaluation of Hereditary Cancer Educational Videos
- Published
- 2024
4. Quebec Pancreas Cancer Study (QPCS)
- Author
-
George Zogopoulos, Principal Investigator
- Published
- 2024
5. CHARGE Study: CHoice ARchitecture Genetic tEsting (CHARGE)
- Author
-
Sukh Makhnoon, Assistant Professor
- Published
- 2024
6. Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
- Author
-
Polan, Rosa M., Ali-Fehmi, Rouba, Grace, Anne K., Mattei, Larissa H., Tanner III, Edward J., and Morris, Robert T.
- Subjects
- *
MINIMALLY invasive procedures , *BRCA genes , *OVARIES , *SALPINGO-oophorectomy , *CANCER invasiveness - Abstract
To describe extension of ovarian tissue beyond visible and National Comprehensive Cancer Network recommended margins among patients with BRCA mutations undergoing minimally invasive risk-reducing salpingo-oophorectomy. A prospective study of patients with BRCA mutations who underwent minimally invasive risk-reducing bilateral salpingo-oophorectomy was conducted. Patient enrollment occurred between October 2021 and 2023. Tissue specimens were analyzed according to the Sectioning and Extensively Examining the Fimbriated End protocol. Twenty women with BRCA mutations were prospectively enrolled. All patients underwent minimally invasive surgery with 70% undergoing concurrent hysterectomy (n = 14). Approximately half of these procedures were performed with robotic assistance (n = 9, 45%). One patient was admitted overnight (5%); the other nineteen were discharged on the day of surgery (95%). One patient experienced a major complication and required readmission (5%). Extension of ovarian tissue beyond the visible ovary was noted on pathologic examination of six specimens (30%). In one patient this was observed on the left (17%), in three on the right (50%), and in two bilateral extension (33%) was noted. The distance ovarian stroma extended microscopically beyond the visible ovary was between 2 and 14 mm, with a median of 5 mm. Among patients with microscopic extension of ovarian tissue, the majority (n = 5, 83%) had a BRCA2 mutation. In women with BRCA mutations undergoing risk-reducing minimally invasive surgery, approximately one third had microscopic extension of ovarian stroma beyond the visible ovary. Current guidelines which recommend resection of at least 20 mm of tissue beyond the visible ovary are likely adequate in this population. • In women with BRCA undergoing risk-reducing minimally invasive surgery, one third had ovarian stroma beyond the visible ovary • Distance ovarian stroma extended microscopically beyond the visible ovary was between 2 and 14 mm, with a median of 5 mm • Current guidelines which recommend resection of 20 mm of tissue beyond the visible ovary are adequate in this population [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Genomics and hereditary cancer syndromes in women's health: a focus on gynaecological management.
- Author
-
Bolton, Helen
- Subjects
RISK assessment ,PATIENT education ,GENOMICS ,BRCA genes ,GENETIC disorders ,WOMEN'S health ,DISEASE susceptibility ,INDIVIDUALIZED medicine ,SOCIAL support ,HEREDITARY cancer syndromes ,DISEASE risk factors - Abstract
Hereditary or familial cancer syndromes are caused by inherited pathogenic variants in cancer susceptibility genes and are associated with an increased risk of developing malignancies occurring at an earlier age. BRCA-associated Hereditary Breast and Ovarian Cancer and Lynch Syndromes are the most common conditions encountered in gynaecology. Identification presents opportunities to prevent or reduce the risk of cancer, or to detect cancers at earlier stages with improved outcomes. When cancer does occur, there may be options for personalized therapeutic approaches. Cancer prevention invariably requires risk-reducing surgical treatment, which may result in irreversible loss of fertility and premature menopause; issues which must be addressed through a personalized management approach. Regular review with adjustments to plans are required as individuals pass through different reproductive life-stages. Comprehensive management requires a multi-professional approach including specialist genetics input, prevention of cancer by education, modification of risk factors and specific interventions, in addition to psychosocial support. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Constitutional Mutation of PIK3CA : A Variant of Cowden Syndrome?
- Author
-
Vida-Navas, Elena, Barca-Tierno, Verónica, López-Gómez, Victoria, Salazar, María Teresa, Moreno-Pelayo, Miguel A., and Guillén-Ponce, Carmen
- Subjects
- *
HEREDITARY cancer syndromes , *OVARIAN cancer , *THYROID cancer , *BREAST cancer , *GENETIC mutation , *FALLOPIAN tubes , *BREAST - Abstract
We present a family in which four individuals have been identified with the same likely pathogenic genetic alteration in the PIK3CA gene at the germinal level; specifically, c.1145G>A p.(Arg382Lys) missense type. The index case patient was diagnosed with multinodular goiter and breast cancer at 61 years old. Among the other three carrier relatives: one has been diagnosed with serous cystadenoma of the ovary and a thyroid nodule with no radiological suspicion of malignancy; the other two present multinodular goiter. Additionally, a sister of three of the carriers suffered from an ovarian teratoma, follicular thyroid carcinoma on multinodular goiter, and high-grade serous ovarian carcinoma. No direct mutation study was performed on her as she had died due to ovarian carcinoma. This finding suggests that the PIK3CA gene should be considered in Cowden-like families when no other gene mutations have been found. Furthermore, this report contributes to characterization of the clinical phenotype caused by mutations in PIK3CA, which may be shared with other hereditary breast and ovarian cancer syndromes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory.
- Author
-
TSOULOS, NIKOLAOS, AGIANNITOPOULOS, KONSTANTINOS, POTSKA, KEVISA, KATSELI, ANASTASIA, NTOGKA, CHRISTINA, PEPE, GEORGIA, BOUZARELOU, DIMITRA, PAPATHANASIOU, ATHANASIOS, GRIGORIADIS, DIMITRIOS, TSAOUSIS, GEORGIOS N., GOGAS, HELEN, TROUPIS, THEODORE, PAPAZISIS, KONSTANTINOS, NATSIOPOULOS, IOANNIS, VENIZELOS, VASSILEIOS, AMARANTIDIS, KYRIAKOS, GIASSAS, STYLIANOS, PAPADIMITRIOU, CHRISTOS, FOUNTZILAS, ELENA, and STATHOULOPOULOU, MAROULIO
- Subjects
NUCLEOTIDE sequencing ,GENETIC testing ,FAMILY history (Medicine) ,CANCER patients ,PROSTATE cancer ,OVARIAN cancer - Abstract
Background/Aim: The application of next generation sequencing (NGS) technology in the genetic investigation of hereditary cancer is important for clinical surveillance, therapeutic approach, and reducing the risk of developing new malignancies. The aim of the study was to explore genetic predisposition in individuals referred for hereditary cancer. Materials and Methods: A total of 8,261 individuals were referred for multigene genetic testing, during the period 2020-2023, in the laboratory, and underwent multigene genetic testing using NGS. Among the examined individuals, 56.17% were diagnosed with breast cancer, 6.77% with ovarian cancer, 2.88% with colorectal cancer, 1.91% with prostate cancer, 6.43% were healthy with a significant family history of cancer, while 3.06% had a different type of cancer and 0.21% had not provided any information. Additionally, in 85 women with breast cancer we performed whole exome sequencing analysis. Results: 20% of the examined individuals carried a pathogenic variant. Specifically, 54.8% of the patients had a pathogenic variant in a clinically significant gene (BRCA1, BRCA2, PALB2, RAD51C, PMS2, CDKN2A, MLH1, MSH2, TP53, MSH6, APC, RAD51D, PTEN, RET, CDH1, MEN1, and VHL). Among the different types of pathogenic variants detected, a significant percentage (6.52%) represented copy number variation (CNV). With WES analysis, the following findings were detected: CTC1: c.880C>T, p.(Gln294*); MLH3: c.405del, p.(Asp136Metfs*2), PPM1D: c.1426_1430del, p.(Glu476Leufs*3), and SDHB: c.395A>G, p.(His132Arg). Conclusion: Comprehensive multigene genetic testing is necessary for appropriate clinical management of pathogenic variants’ carriers. Additionally, the information obtained is important for determining the risk of malignancy development in family members of the examined individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. A Prospective Questionnaire-Based Study Evaluating Genetic Literacy and Impact of Brief Educational Intervention Among Breast Cancer Patients in a Low- to Middle-Income Country.
- Author
-
Mishra, Ashutosh, Deo, S. V. S., Kumar, Navin, Bansal, Babul, Gogia, Ajay, Pramanik, Raja, Batra, Atul, Sharma, D. N., Mathur, Sandeep, and Pathak, Mona
- Abstract
Introduction: A significant proportion of breast cancer cases are hereditary and are potentially preventable. However, adoption of the preventive measures remains a significant challenge, particularly because of to lack of knowledge and awareness in low- to middle-income countries. Methods: This prospective study conducted at a high-volume tertiary care cancer center in North India to assess the knowledge, awareness, and attitudes of female breast cancer patients and impact of a brief educational intervention. The study involved three phases: pre-interventional assessment, educational intervention, and post-interventional assessment utilizing a structured questionnaire. Results: The study involved 300 newly diagnosed breast cancer patients; 16.7% were familial. At the outset, 87.0% patients had low knowledge of risk factors, 90.3% about screening, and 32.7% about treatment. Awareness levels were low: 13.7% aware of familial risk and 2.7% of breast cancer genes. Affordability of genetic testing was low (15.2%), and interest in testing for self and family members was limited (32.0% and 26.3%). Following educational intervention, a significant positive percentage change was noticed in knowledge (risk factors: 12.8%, screening: 36.2%, treatment: 82%), awareness (familial risk: 66.7%, BRCA gene: 12.3%), and attitude (testing for self: 17.8%, family: 19.5%). Conclusions: This study highlights the significant knowledge gaps among breast cancer patients regarding genetics. The educational intervention led to notable improvements in knowledge, awareness, and attitudes, underscoring the importance of tailored patient education in breast cancer care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance.
- Author
-
Berry, Darcy K., Gillis, Nancy, Padron, Eric, Moore, Colin, Barton, Laura V., Gewandter, Kathleen R., Haskins, Carolyn G., and Knepper, Todd C.
- Abstract
The increased use of next‐generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li–Fraumeni syndrome (LFS). These variants can represent low‐penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these variants can be challenging but is crucial for an accurate diagnosis and appropriate medical management. This retrospective case review provides illustrative examples of the interpretation of challenging TP53 results through multidisciplinary expertise and use of a flowchart. The authors describe eight patients with TP53 variants associated with ambiguous diagnoses and, for each case, describe how the results were interpreted and the medical care that was implemented. This report presents illustrative cases to help guide clinicians to reach definitive diagnoses for patients when confronted with TP53 variants that are inconsistent with the clinical picture and to add to the body of literature regarding interpretation and medical management of TP53 variants discovered on germline testing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Penn Biobank Return of Research Results Program
- Author
-
Fox Chase Cancer Center
- Published
- 2023
13. The DIALOGUE Study: Swiss-Korean Billateral Collaboration (DIALOGUE)
- Author
-
Yonsei University, University Hospital, Basel, Switzerland, Hopital du Jura, Delemont, Switzerland, Department of Computer Science Yonsei University, Seoul, Korea, National Cancer Center, Korea, Chungnam National University, Ente Ospedaliero Cantonale, Ticino, Switzerland, Swiss National Science Foundation, Insel Gruppe AG, University Hospital Bern, University Hospital, Geneva, and Maria Katapodi, Professor of Nursing Science, Department of Clinical Research
- Published
- 2023
14. "Identity theft" in BRCA1/2: impact of positive genetic test results and risk-reducing interventions.
- Author
-
Adler, Jonathan M., Hesse-Biber, Sharlene, Seven, Memnun, and Dwyer, Andrew A.
- Subjects
IDENTITY theft ,GENETIC testing ,BRCA genes ,IDENTITY (Psychology) ,PATIENT experience - Abstract
Individuals harboring breast cancer gene 1/2 (BRCA1/2) pathogenic variants are at increased lifetime risk for developing cancer. Learning one's BRCA1/2 carrier status is a watershed moment that can result in psychological distress, anxiety, and depression, as well as feelings of vulnerability and stigma. However, emotional and coping responses to learning one's BRCA1/2 carrier status and after risk-reducing interventions (i.e., preventative bilateral mastectomy) are variable, and existing literature reveals mixed and sometimes contradictory results. Drawing on the concept of narrative identity from the field of psychology, we sought to examine if "identity theft" (the sudden overtaking of one's narrative agency by an external force) may help explain the heterogeneity of emotional and coping responses following the revelation of BRCA carrier status and the subsequent medical intervention one may receive. This Perspective explores BRCA related identity theft using two case studies. Narrative analysis of qualitative interviews uncover the ways that patients experience the disintegration (theft) of their identity as well as their efforts to build and reintegrate a new BRCA carrier identity. This initial qualitative exploration provides preliminary support for the relevance of narrative identity and identity theft to hereditary cancer. We posit that applying the lens of identity theft may hold promise as a unifying concept, integrating across the variable emotional and coping responses among BRCA carriers. Employing a lens of identity theft may help inform the development of tailored narrative interventions as part of precision healthcare to support active coping and psychosocial wellbeing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. The Crucial Role of Hereditary Cancer Panel Testing in Unaffected Individuals with a Strong Family History of Cancer: A Retrospective Study of a Cohort of 103 Healthy Subjects.
- Author
-
Pilenzi, Lucrezia, Anaclerio, Federico, Dell'Elice, Anastasia, Minelli, Maria, Giansante, Roberta, Cicirelli, Michela, Tinari, Nicola, Grassadonia, Antonino, Pantalone, Andrea, Grossi, Simona, Canale, Nicole, Bruno, Annalisa, Calabrese, Giuseppe, Ballerini, Patrizia, Stuppia, Liborio, and Antonucci, Ivana
- Subjects
- *
TUMOR risk factors , *RISK assessment , *GENOMICS , *FAMILIES , *RETROSPECTIVE studies , *MEDICAL records , *ACQUISITION of data , *ONCOGENES , *GENETIC mutation , *INDIVIDUALIZED medicine , *GENETIC testing , *SEQUENCE analysis ,TUMOR genetics - Abstract
Simple Summary: The purpose of this study is to emphasize the importance of genetic testing for healthy individuals with a strong family history of hereditary malignancies. A total of 103 healthy subjects with at least two relatives with cancer were enrolled. By NGS analysis of 27 genes, 5% were found to carry a pathogenic variant in a hereditary cancer susceptibility gene. In the era of personalized medicine, genetic testing of healthy subjects in the absence of a living affected collateral is crucially important for early diagnosis, clinical surveillance and surgical choice. Hereditary cancer syndromes caused by germline mutations account for 5–10% of all cancers. The finding of a genetic mutation could have far-reaching consequences for pharmaceutical therapy, personalized prevention strategies, and cascade testing. According to the National Comprehensive Cancer Network's (NCCN) and the Italian Association of Medical Oncology (AIOM) guidelines, unaffected family members should be tested only if the affected one is unavailable. This article explores whether germline genetic testing may be offered to high-risk families for hereditary cancer even if a living affected relative is missing. A retrospective study was carried out on 103 healthy subjects tested from 2017 to 2023. We enrolled all subjects with at least two first- or second-degree relatives affected by breast, ovarian, pancreatic, gastric, prostate, or colorectal cancer. All subjects were tested by Next Generation Sequencing (NGS) multi-gene panel of 27 cancer-associated genes. In the study population, 5 (about 5%) pathogenic/likely pathogenic variants (PVs/LPVs) were found, while 40 (42%) had a Variant of Uncertain Significance (VUS). This study highlights the importance of genetic testing for individuals with a strong family history of hereditary malignancies. This approach would allow women who tested positive to receive tailored treatment and prevention strategies based on their personal mutation status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. TP53 p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest Brazil.
- Author
-
Corrêa, Tatiana Strava, Asprino, Paula Fontes, de Oliveira, Eduarda Sabá Cordeiro, Leite, Ana Carolina Rathsam, Weis, Luiza, Achatz, Maria Isabel, de Oliveira, Claudiner Pereira, Sandoval, Renata Lazari, and Barroso-Sousa, Romualdo
- Subjects
- *
GENETIC carriers , *LI-Fraumeni syndrome , *BREAST cancer , *GENETIC testing , *DUCTAL carcinoma , *BREAST - Abstract
Despite the high prevalence of TP53 pathogenic variants (PV) carriers in the South and Southeast regions of Brazil, germline genetic testing for hereditary breast cancer (HBC) is not available in the Brazilian public health system, and the prevalence of Li-Fraumeni syndrome (LFS) is not well established in other regions of Brazil. We assessed the occurrence of TP53 p.R337H carriers among women treated for breast cancer (BC) between January 2021 and January 2022 at public hospitals of Brasilia, DF, Brazil. A total of 180 patients who met at least one of the NCCN criteria for HBC underwent germline testing; 44.4% performed out-of-pocket germline multigene panel testing, and 55.6% were tested for the p.R337H variant by allelic discrimination PCR. The median age at BC diagnosis was 43.5 years, 93% had invasive ductal carcinoma, 50% had estrogen receptor-positive/HER2 negative tumors, and 41% and 11% were diagnosed respectively at stage III and IV. Two patients (1.11%) harbored the p.R337H variant, and cascade family testing identified 20 additional carriers. The TP53 p.R337H detection rate was lower than that reported in other studies from south/southeast Brazil. Nonetheless, identifying TP53 PV carriers through genetic testing in the Brazilian public health system could guide cancer treatment and prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research.
- Author
-
Ibrahim, Maria Baz, Flanagan, James, Ibrahim, Tony, and Rouleau, Etienne
- Abstract
Exhaustive efforts have been dedicated to uncovering genomic aberrations linked to cancer susceptibility. Noncoding sequence variants and epigenetic alterations significantly influence gene regulation and could contribute to cancer development. However, exploring noncoding regions in hereditary cancer susceptibility demands cutting-edge methodologies for functionally characterizing genomic discoveries. Additionally, comprehending the impact on cancer development of variants in noncoding DNA and the epigenome necessitates integrating diverse data through bioinformatic analyses. As novel technologies and analytical methods continue to advance, this realm of research is rapidly gaining traction. Within this mini-review, we delve into future research domains concerning aberrations in noncoding DNA regions, such as pseudoexons, promoter variants and cis-epimutations. Executive summary Introduction 5–10% of cancer cases are attributed to highly penetrant hereditary cancer syndromes. Survivors with hereditary predispositions remain susceptible to secondary neoplasia. High-throughput next-generation sequencing and multigene panels enhance mutation screening, but challenges persist in identifying germline aberrations linked to cancer susceptibility. Investigating noncoding regions Traditionally, the focus has been on coding regions; however, noncoding regions are crucial for gene regulation and genome stability. Large-scale genomics initiatives (ENCODE, FANTOM5, Epigenomics Roadmap, GTEx Consortium) explore noncoding regions and the epigenome. Noncoding DNA projects aim to comprehensively identify and characterize functional elements, enhancing understanding of gene regulation. Noncoding germline variants Introns and pseudoexons harbor variants impacting mRNA splice sites. Pseudoexons, often caused by pathogenic variants, challenge conventional diagnostic methods. Promoter variants in noncoding regions, identified in BRCA and PTEN, inhibit or activate gene expression. Germline variants disrupt noncoding RNA biosynthesis, affecting downstream targets and contributing to cancer susceptibility. Epigenetics Epigenetic changes (reversible modifications to DNA and histones) play a key role in tumorigenesis. DNA methylation, histone modifications, chromatin remodeling and noncoding RNAs influence gene expression. Abnormal epigenetic inheritance, coupled with environmental factors, increases cancer predisposition. Epimutations & methylations in hereditary cancer Germline promoter methylation (epimutations) silences tumor suppressor genes, contributing to cancer susceptibility. BRCA1 and BRCA2 promoter methylation are associated with hereditary breast and ovarian cancers. Epigenetic changes may persist across generations, impacting gene expression and cancer risk. Limitations & future perspective Investigating noncoding regions poses challenges and demands advanced methodologies for effective genomic characterization. Advanced genomics techniques: chromatin immunoprecipitation and sequencing, DNase-seq, Assay for Transposase-Accessible Chromatin with highthroughput sequencing (ATAC-seq) play a pivotal role in assessing the functionality of noncoding variants. Bioinformatic analyses are crucial for comprehending the impact of noncoding variants on genome structure and cancer progression. Further studies are needed to explore the prevalence and clinical significance of noncoding variants in patients with seemingly sporadic cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Medullary Thyroid Cancer: Epidemiology and Characteristics According to Data From the Marne-Ardennes Register 1975-2018.
- Author
-
Caillé, Sarah, Debreuve-Theresette, Adeline, Vitellius, Géraldine, Deguelte, Sophie, Manna, Luigi La, and Zalzali, Mohamad
- Subjects
MEDULLARY thyroid carcinoma ,THYROID cancer ,EPIDEMIOLOGY of cancer ,SURVIVAL analysis (Biometry) ,SURVIVAL rate ,SEX ratio - Abstract
Context Medullary thyroid cancer (MTC) is a rare disease. Objective The main objective of our study was to analyze the incidence evolution of MTC with a follow-up of more than 40 years. Further, a descriptive and survival analysis was performed according to the Kaplan–Meier analysis. Design, Setting, and Patients This is a retrospective epidemiological study using data from the Marne-Ardennes registry from 1975 to 2018. Two hundred sixty patients with MTC were included. Main Outcome Measures The incidence was calculated in the territory of the register (Marne and Ardennes departments of France) and standardized on the demographic structure of France. Patient and tumor characteristics were described. An analysis in a subgroup comparing hereditary and sporadic forms was performed. An analysis of survival was performed. Results The standardized incidence shows an increasing trend over time. The incidence increased significantly from 0.41 to 0.57/100 000 person-years between 1986 and 1996 and 2008 and 2018. The MTC was hereditary in 21.2% of cases. The sex ratio (males:females) was 0.73. The average age at diagnosis was 53 years. Ninety-seven patients (37.3%) were N1, 26 (10%) were M1, and 56 (21.5%) developed metastases during the follow-up. Complete remission was obtained in 58.5% of patients. The disease was refractory for 18.1% of patients. The 5-year survival rate was 88.4%. Sporadic cases had a poorer prognosis than hereditary MTC. Conclusion Our study demonstrates a moderate increase in the incidence of MTC between 1975 and 2018. The prognosis remains worse for sporadic MTC than for hereditary MTC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Cascade testing for hereditary cancer in Singapore: how population genomics help guide clinical policy.
- Author
-
Caeser, Rebecca, Chiang, Jianbang, Tan, Ee Shien, Tai, E Shyong, and Ngeow, Joanne
- Subjects
GENETIC testing ,GENOMICS ,LONG-term health care ,INDIVIDUALIZED medicine ,RELATIVES ,CANCER diagnosis - Abstract
Hereditary Cancer makes up around 5–10% of all cancers. It is important to diagnose hereditary cancer in a timely fashion, as not only do patients require long-term care from a young age, but their relatives also require management. The main approach to capture at-risk relatives is cascade testing. It involves genetic testing of relatives of the first detected carrier of a pathogenic variant in a family i.e. the proband. The current standard of care for cascade testing is a patient-mediated approach. Probands are then advised to inform and encourage family members to undergo genetic testing. In Singapore, cascade testing is inefficient, around 10–15%, lower than the 30% global average. Here, we describe the cascade testing process and its effort to increase testing in Singapore. Precision Health Research, Singapore (PRECISE), was set up to coordinate Singapore's National Precision Medicine strategy and has awarded five clinical implementation pilots, with one of them seeking to identify strategies for how cascade testing for hereditary cancer can be increased in a safe and cost-efficient manner. Achieving this will be done through addressing barriers such as cost, manpower shortages, exploring a digital channel for contacting at-risk relatives, and getting a deeper insight into why genetic testing gets declined. If successful, it will likely result in care pathways that are a cost-effective public health intervention for identifying individuals at risk. Surveillance and management of those unaffected at-risk individuals, if caught early, will result in improved patient outcomes, and further reduce the healthcare burden for the economy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. A content analysis of parents’ reflections on pathogenic and uncertain pediatric oncology germline sequencing results
- Author
-
Howard Sharp, Katianne M., Clark, Mary Egan, Jurbergs, Niki, Ouma, Annastasia, Harrison, Lynn, Taylor, Leslie, Hamilton, Kayla, McGee, Rose B., Nuccio, Regina, Hines-Dowell, Stacy, Gattuso, Jami S., Pritchard, Michelle, Mandrell, Belinda, Tercyak, Kenneth P., Johnson, Liza-Marie, and Nichols, Kim E.
- Published
- 2024
- Full Text
- View/download PDF
21. Circulating metabolome landscape in Lynch syndrome
- Author
-
Tiina A. Jokela, Jari E. Karppinen, Minta Kärkkäinen, Jukka-Pekka Mecklin, Simon Walker, Toni T. Seppälä, and Eija K. Laakkonen
- Subjects
Metabolomic biomarkers ,DNA mismatch repair deficiency ,Hereditary cancer ,Lipid metabolism ,Cholesterol metabolism ,Circulating amino acids ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Circulating metabolites systemically reflect cellular processes and can modulate the tissue microenvironment in complex ways, potentially impacting cancer initiation processes. Genetic background increases cancer risk in individuals with Lynch syndrome; however, not all carriers develop cancer. Various lifestyle factors can influence Lynch syndrome cancer risk, and lifestyle choices actively shape systemic metabolism, with circulating metabolites potentially serving as the mechanical link between lifestyle and cancer risk. This study aims to characterize the circulating metabolome of Lynch syndrome carriers, shedding light on the energy metabolism status in this cancer predisposition syndrome. This study consists of a three-group cross-sectional analysis to compare the circulating metabolome of cancer-free Lynch syndrome carriers, sporadic colorectal cancer (CRC) patients, and healthy non-carrier controls. We detected elevated levels of circulating cholesterol, lipids, and lipoproteins in LS carriers. Furthermore, we unveiled that Lynch syndrome carriers and CRC patients displayed similar alterations compared to healthy non-carriers in circulating amino acid and ketone body profiles. Overall, cancer-free Lynch syndrome carriers showed a unique circulating metabolome landscape. This study provides valuable insights into the systemic metabolic landscape of Lynch syndrome individuals. The findings hint at shared metabolic patterns between cancer-free Lynch syndrome carriers and CRC patients.
- Published
- 2024
- Full Text
- View/download PDF
22. No Racial Disparities Observed Using Point-of-Care Genetic Counseling and Testing for Endometrial and Ovarian Cancer in a Diverse Patient Population: A Retrospective Cohort Study.
- Author
-
Kim, Michael, Hayek, Judy, Acker, Cheyenne, An, Anjile, Zhang, Peilin, Gorelick, Constantine, and Kanis, Margaux J.
- Subjects
- *
CONSENSUS (Social sciences) , *INSURANCE , *RESEARCH funding , *OVARIAN tumors , *GENETIC counseling , *RETROSPECTIVE studies , *TERTIARY care , *DESCRIPTIVE statistics , *RACE , *ENDOMETRIAL tumors , *IMMUNOHISTOCHEMISTRY , *HEALTH equity , *POINT-of-care testing , *FALLOPIAN tubes , *ONCOLOGISTS , *COUNSELING , *GENETIC testing , *MEDICAL referrals - Abstract
Simple Summary: Despite consensus recommendations, national genetic counseling and testing rates for gynecological cancers remain relatively low. Prior studies have also shown that referrals are fewer for people of minority backgrounds. This initial study aimed to determine what genetic counseling and testing rates are found in a diverse patient setting. High rates of genetic counseling and testing are demonstrated, with no racial disparities. Both endometrial and ovarian cancer data are presented simultaneously in a single study in the first of its kind, helping provide a broader combined perspective. Point-of-care genetic counseling and testing by gynecologic oncologists is a strategy that can be similarly adopted at other institutions to potentially reduce disparities. Further studies can identify other factors responsible for the successful counseling and testing rates and how they can be used to broaden the reach of these services at other centers with similar diverse populations. We investigated genetic counseling and testing rates for patients with gynecologic malignancy at a tertiary care center with a large minority population. Our retrospective cohort included newly diagnosed epithelial ovarian, fallopian tube, peritoneal, or endometrial cancer patients between January 2014 and June 2022. For endometrial cancer, 373 patients were identified. A total of 207 (55%) patients were screened using mismatch repair immunohistochemistry (MMR IHC). A total of 82 (40%) had MMR deficiencies on IHC. Of these, 63 (77%) received genetic counseling. A total of 62 (98%) underwent genetic testing, and ultimately, 7 (11%) were diagnosed with Lynch syndrome (LS). The overall rate of LS was 1.9%. MMR IHC testing increased steadily, reaching 100% in 2022. For ovarian cancer, 144 patients were identified. A total of 104 (72%) patients received genetic counseling, and 99 (95%) underwent genetic testing. Rates were not influenced by race, ethnicity, insurance type, or family history of cancer. They were significantly different by cancer stage (p < 0.01). The proportion of patients who received genetic counseling increased from 47% in 2015 to 100% in 2022 (p < 0.01). Most counseling was performed by a gynecologic oncologist (93%) as opposed to a genetic counselor (6.7%). Overall, 12 (8.3%) patients were BRCA+. High rates of counseling and testing were observed with few disparities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Integration and usability of a digital cancer risk stratification tool to optimize identification of patients at risk for hereditary cancers: A pilot study.
- Author
-
Webster, Emily M., Perez, Luiza, Ahsan, Muhammad Danyal, Levi, Sarah, Chandler, Isabelle, Thomas, Charlene, Babagbemi, Kemi, Sharaf, Ravi N., and Frey, Melissa K.
- Subjects
- *
DISEASE risk factors , *MEDICAL screening , *HEALTH literacy , *RACE , *CANCER patients - Abstract
Patients with a personal or family history of cancer may have elevated risk of developing future cancers, which often remains unrecognized due to lapses in screening. This pilot study assessed the usability and clinical outcomes of a cancer risk stratification tool in a gynecologic oncology clinic. New gynecologic oncology patients were prompted to complete a commercially developed personal and family history-based risk stratification tool to assess eligibility for genetic testing using National Comprehensive Cancer Network criteria and estimated lifetime breast cancer risk using the Tyrer-Cuzick model. After use of the risk stratification tool, usability was assessed via completion rate and the System Usability Scale, and health literacy was assessed using the BRIEF Health Literacy Screening Tool. 130 patients were prompted to complete the risk stratification tool; 93 (72%) completed the tool. Race and ethnicity and insurance type were not associated with tool completion. The median System Usability Scale score was 83 out of 100 (interquartile range, 60–95). Health literacy positively correlated with perceived usability. Public insurance and race or ethnicity other than non-Hispanic White was associated with lower perceived usability. Sixty (65%) patients met eligibility criteria for genetic testing, and 21 (38% of 56 eligible patients) were candidates for enhanced breast cancer screening based on an estimated lifetime breast cancer risk of ≥20%. A majority of patients completed the digital cancer risk stratification tool. Older age, lower health literacy, public insurance, and race or ethnicity other than non-Hispanic White were associated with lower perceived tool usability. • A digital cancer risk stratification tool assessed genetic testing eligibility and lifetime breast cancer risk. • Uptake of the digital cancer risk stratification tool was high and usability scores were favorable. • Age, health literacy, primary insurance, and race and ethnicity were associated with perceived tool usability. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Preferences for Genetic Testing to Predict the Risk of Developing Hereditary Cancer: A Systematic Review of Discrete Choice Experiments.
- Author
-
Morrish, N., Snowsill, T., Dodman, S., and Medina-Lara, A.
- Abstract
Background: Understanding service user preferences is key to effective health care decision making and efficient resource allocation. It is of particular importance in the management of high-risk patients in whom predictive genetic testing can alter health outcomes. Purpose: This review aims to identify the relative importance and willingness to pay for attributes of genetic testing in hereditary cancer syndromes. Data Sources: Searches were conducted in Medline, Embase, PsycINFO, HMIC, Web of Science, and EconLit using discrete choice experiment (DCE) terms combined with terms related to hereditary cancer syndromes, malignancy synonyms, and genetic testing. Study Selection: Following independent screening by 3 reviewers, 7 studies fulfilled the inclusion criteria, being a DCE investigating patient or public preferences related to predictive genetic testing for hereditary cancer syndromes. Data Extraction: Extracted data included study and respondent characteristics, DCE attributes and levels, methods of data analysis and interpretation, and key study findings. Data Synthesis: Studies covered colorectal, breast, and ovarian cancer syndromes. Results were summarized in a narrative synthesis and the quality assessed using the Lancsar and Louviere framework. Limitations: This review focuses only on DCE design and testing for hereditary cancer syndromes rather than other complex diseases. Challenges also arose from heterogeneity in attributes and levels. Conclusions: Test effectiveness and detection rates were consistently important to respondents and thus should be prioritized by policy makers. Accuracy, cost, and wait time, while also important, showed variation between studies, although overall reduction in cost may improve uptake. Patients and the public would be willing to pay for improved detection and clinician over insurance provider involvement. Future studies should seek to contextualize findings by considering the impact of sociodemographic characteristics, health system coverage, and insurance policies on preferences. Highlights: Test effectiveness and detection rates are consistently important to respondents in genetic testing for hereditary cancer syndromes. Reducing the cost of genetic testing for hereditary cancer syndromes may improve uptake. Individuals are most willing to pay for a test that improves detection rates, identifies multiple cancers, and for which results are shared with a doctor rather than with an insurance provider. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Uptake of genetic testing among patients seeking cancer genetic counseling in Taiwan.
- Author
-
Fang, Su‐Ying, Hsieh, Ling‐Ling, Hung, Chen‐Fang, and Wang, Yong Alison
- Abstract
Genetic testing is becoming increasingly available and affordable. Understanding the reasons for individual decisions about genetic testing may assist in the identification of clinically appropriate use of genetic counseling and genetic testing resources. With the ongoing development of cancer genetic counseling services in Taiwan, we conducted this study to understand the characteristics of those seeking cancer genetic counseling and genetic testing and the predictors for undergoing genetic testing after counseling. Cross‐sectional with correlational design was used in this study. Surveys completed by patients visiting the genetic counseling clinic at the cancer center included demographics, personal and family history of cancer, and questions on attitudes toward genetic counseling and genetic testing. Multinomial logistic regression was used to analyze the predictors of decision to undergo genetic testing. A total of 120 participants between the years 2018 and 2021 were analyzed, of which 54.2% were referred by health care professionals. The majority (76.7%) had a personal history of cancer and 50% had breast cancer. Over half (53.3%) had a strong family history of cancer defined as two or more 1st‐degree relatives having cancer at a young age. Only 35.8% decided to receive genetic testing right after counseling and 47.5% were undecided. The main reason for hesitation or not pursuing testing was cost (41.4%). Multivariate logistic regression analysis showed that a positive attitude toward genetic counseling was significantly associated with the uptake of genetic testing (Odds ratio 7.60, 95% CI 2.34–24.66, p < 0.001). Given the significant number of individuals undecided about genetic testing after counseling, decision aid could be developed to support genetic counseling and increase satisfaction with the testing decision. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. The history of families at-risk for hereditary breast and ovarian cancer: what are the impacts of genetic counseling and testing?
- Author
-
Campacci, Natalia, Silveira Grasel, Rebeca, de Campos Reis Galvão, Henrique, França Garcia, Lucas, Carvalho Ribeiro, Paula, de Jesus de Sena Pereira, Kercy Fram, Goldim, José Roberto, Ashton-Prolla, Patricia, and Palmero, Edenir Inêz
- Subjects
GENETIC counseling ,OVARIAN cancer ,GENETIC testing ,MEDICAL personnel ,BREAST cancer ,HEREDITARY cancer syndromes ,AT-risk youth - Abstract
Introduction: Cancer Genetic Counseling (CGC) and genetic testing (GT) assume a paramount role for hereditary cancer predisposition syndrome families. We assessed the effects of CGC and GT on women affected by cancer who are at risk for hereditary breast and ovarian cancer predisposition syndrome (HBOC). Methods: This study encompasses four time points: before the CGC session, after the CGC session when blood is drawn for GT, after disclosure of GT results, and six months following disclosure of GT results. The impacts of CGC and GT were assessed using psychosocial questionnaires. Additionally, a pedigree, genogram, and ecomap were constructed through a semistructured interview. Results: A total of sixty women were included in the study. Most participants considered their perception of cancer risk to be equivalent to that of the general population, even among those with pathogenic variants. An increased perception of breast and ovarian cancer risks was associated with a heightened inclination toward religious engagement as a coping mechanism. Patients carrying variants of uncertain significance expressed greater concerns about developing another cancer compared to those who had BRCA1 and BRCA2 wild type or pathogenic variants. Qualitative analysis of the genograms and ecomaps demonstrated that the CGC/GT processes facilitate communication within families. The genogram analyses revealed the impact of CGC and GT processes on families at risk for hereditary cancer. Changes in some family relationships were observed, and an improvement in communication was noted following the GT process. Discussion: These findings can assist healthcare professionals considering a personalized approaches in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Investigating USP42 Mutation as Underlying Cause of Familial Non-Medullary Thyroid Carcinoma.
- Author
-
Teixeira, Elisabete, Fernandes, Cláudia, Bungărdean, Maria, Paula, Arnaud Da Cruz, Lima, Raquel T., Batista, Rui, Vinagre, João, Sobrinho-Simões, Manuel, Máximo, Valdemar, and Soares, Paula
- Subjects
- *
THYROID cancer , *CYTOLOGY , *GENETIC mutation , *MISSENSE mutation , *GENE silencing , *THYROTROPIN receptors - Abstract
In a family with Familial Non-Medullary Thyroid Carcinoma (FNMTC), our investigation using Whole-Exome Sequencing (WES) uncovered a novel germline USP42 mutation [p.(Gly486Arg)]. USP42 is known for regulating p53, cell cycle arrest, and apoptosis, and for being reported as overexpressed in breast and gastric cancer patients. Recently, a USP13 missense mutation was described in FNMTC, suggesting a potential involvement in thyroid cancer. Aiming to explore the USP42 mutation as an underlying cause of FNMTC, our team validated the mutation in blood and tissue samples from the family. Using immunohistochemistry, the expression of USP42, Caspase-3, and p53 was assessed. The USP42 gene was silenced in human thyroid Nthy-Ori 3-1 cells using siRNAs. Subsequently, expression, viability, and morphological assays were conducted. p53, Cyclin D1, p21, and p27 proteins were evaluated by Western blot. USP42 protein was confirmed in all family members and was found to be overexpressed in tumor samples, along with an increased expression of p53 and cleaved Caspase-3. siRNA-mediated USP42 downregulation in Nthy-Ori 3-1 cells resulted in reduced cell viability, morphological changes, and modifications in cell cycle-related proteins. Our results suggest a pivotal role of USP42 mutation in thyroid cell biology, and this finding indicates that USP42 may serve as a new putative target in FNMTC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Circulating metabolome landscape in Lynch syndrome.
- Author
-
Jokela, Tiina A., Karppinen, Jari E., Kärkkäinen, Minta, Mecklin, Jukka-Pekka, Walker, Simon, Seppälä, Toni T., and Laakkonen, Eija K.
- Subjects
HEREDITARY nonpolyposis colorectal cancer ,COLORECTAL cancer ,DNA mismatch repair ,AMINO ketones ,ENERGY metabolism - Abstract
Circulating metabolites systemically reflect cellular processes and can modulate the tissue microenvironment in complex ways, potentially impacting cancer initiation processes. Genetic background increases cancer risk in individuals with Lynch syndrome; however, not all carriers develop cancer. Various lifestyle factors can influence Lynch syndrome cancer risk, and lifestyle choices actively shape systemic metabolism, with circulating metabolites potentially serving as the mechanical link between lifestyle and cancer risk. This study aims to characterize the circulating metabolome of Lynch syndrome carriers, shedding light on the energy metabolism status in this cancer predisposition syndrome. This study consists of a three-group cross-sectional analysis to compare the circulating metabolome of cancer-free Lynch syndrome carriers, sporadic colorectal cancer (CRC) patients, and healthy non-carrier controls. We detected elevated levels of circulating cholesterol, lipids, and lipoproteins in LS carriers. Furthermore, we unveiled that Lynch syndrome carriers and CRC patients displayed similar alterations compared to healthy non-carriers in circulating amino acid and ketone body profiles. Overall, cancer-free Lynch syndrome carriers showed a unique circulating metabolome landscape. This study provides valuable insights into the systemic metabolic landscape of Lynch syndrome individuals. The findings hint at shared metabolic patterns between cancer-free Lynch syndrome carriers and CRC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Retrospective chart analysis to determine the impact of a patient-facing digital risk stratification tool combined with a clinical screener for hereditary cancer genetic risk assessment triage in a community oncology clinic.
- Author
-
Shane-Carson, Kate P., Smith, Douglas, Smith, Angie, and Seeley, Caroline
- Abstract
The purpose of this study was to evaluate the utility of adding a clinical screener to the patient-facing digital risk stratification tool triage process for the identification of patients eligible for a genetic risk assessment for hereditary cancer. Digital risk stratification entries were retrospectively reviewed to determine the overall number of patients eligible for genetic risk assessment. These were also analyzed to determine how many patients were re-contacted by the clinical screener, and how many of those recontacted patients met criteria after their personal and family history was revised by the clinical screener. There was an 89.9% digital risk stratification triage tool completion rate, with 22.6% requiring contact from the clinical screener. Of the 640 patients who completed the digital tool, 5.9% met criteria for testing after their personal and/or family history was revised by the clinical screener. Overall, 51.1% of patients met criteria for a genetic risk assessment. The addition of a clinical screener further increased identification of patients eligible for genetic risk assessment. About half of patients who met criteria after being contacted by the clinical screener met criteria based on their personal diagnosis of cancer alone. Incorporation of a clinical screener to the digital screening process may serve to reduce barriers to patient completion of the tool and increase rates of patient identification for cancer genetic services. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Validation of the modified Chinese Information and Support Needs Questionnaire (ISNQ-C) for daughters of mothers with breast cancer.
- Author
-
Fang, Su-Ying and Chen, Ting-Chun
- Abstract
Background: Adult daughters concerned about getting breast cancer throughout their lives and required support because their mothers had breast cancer. Objectives: This article aims to examine the revised Information and Support Needs Questionnaire (ISNQ) and validate it in a Taiwanese community population comprising daughters of mothers with breast cancer. Methods: Using convenience sampling, daughters of mothers with breast cancer were recruited and were separated into 2 samples (Sample 1, n = 102, and Sample 2, n = 118). First, we translated and modified the ISNQ to ensure cultural adaptation and formed ISNQ Chinese version (ISNQ-C). Second, we conducted an exploratory factor analysis using both samples to explore the ISNQ-C factor structure. Finally, we tested the criterion validity and known‐group validity of the ISNQ-C using Sample 2. Results: Thirty-two items addressing 5 factors were identified for the ISNQ‐C. Each factor had good internal consistency. The criterion validity was supported by significant correlations between the ISNQ‐C scores and scores on the impacts of an event, anxiety, and depression. Known‐group comparisons revealed that the group with deceased mothers reported significantly more unmet needs related to "releasing my anxiety" compared to the group where the mother was stable and undergoing regular follow-ups. Significance of results: The ISNQ‐C demonstrated good reliability and validity in terms of assessing needs among daughters of mothers with breast cancer in Taiwan. Using this assessment tool before genetic counseling to target the individual needs of this population at risk for breast cancer would be helpful to provide personalized care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. 'Identity theft' in BRCA1/2: impact of positive genetic test results and risk-reducing interventions
- Author
-
Jonathan M. Adler, Sharlene Hesse-Biber, Memnun Seven, and Andrew A. Dwyer
- Subjects
breast cancer ,coping ,genetic testing ,hereditary cancer ,narrative identity ,identity theft ,Genetics ,QH426-470 - Abstract
Individuals harboring breast cancer gene 1/2 (BRCA1/2) pathogenic variants are at increased lifetime risk for developing cancer. Learning one’s BRCA1/2 carrier status is a watershed moment that can result in psychological distress, anxiety, and depression, as well as feelings of vulnerability and stigma. However, emotional and coping responses to learning one’s BRCA1/2 carrier status and after risk-reducing interventions (i.e., preventative bilateral mastectomy) are variable, and existing literature reveals mixed and sometimes contradictory results. Drawing on the concept of narrative identity from the field of psychology, we sought to examine if “identity theft” (the sudden overtaking of one’s narrative agency by an external force) may help explain the heterogeneity of emotional and coping responses following the revelation of BRCA carrier status and the subsequent medical intervention one may receive. This Perspective explores BRCA related identity theft using two case studies. Narrative analysis of qualitative interviews uncover the ways that patients experience the disintegration (theft) of their identity as well as their efforts to build and reintegrate a new BRCA carrier identity. This initial qualitative exploration provides preliminary support for the relevance of narrative identity and identity theft to hereditary cancer. We posit that applying the lens of identity theft may hold promise as a unifying concept, integrating across the variable emotional and coping responses among BRCA carriers. Employing a lens of identity theft may help inform the development of tailored narrative interventions as part of precision healthcare to support active coping and psychosocial wellbeing.
- Published
- 2024
- Full Text
- View/download PDF
32. Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies
- Author
-
Jocelyn N. Plowman, Evanjalina J. Matoy, Lavanya V. Uppala, Samantha B. Draves, Cynthia J. Watson, Bridget A. Sefranek, Mark L. Stacey, Samuel P. Anderson, Michael A. Belshan, Elizabeth E. Blue, Chad D. Huff, Yusi Fu, and Holly A.F. Stessman
- Subjects
Cancer ,Hereditary cancer ,Lynch Syndrome ,Hereditary breast and ovarian cancer (HBOC) syndrome ,Targeted sequencing ,Variants of undetermined significance ,Genetics ,QH426-470 - Abstract
Summary: Approximately 20% of breast cancer cases are attributed to increased family risk, yet variation in BRCA1/2 can only explain 20%–25% of cases. Historically, only single gene or single variant testing were common in at-risk family members, and further sequencing studies were rarely offered after negative results. In this study, we applied an efficient and inexpensive targeted sequencing approach to provide molecular diagnoses in 245 human samples representing 134 BRCA mutation-negative (BRCAX) hereditary breast and ovarian cancer (HBOC) families recruited from 1973 to 2019 by Dr. Henry Lynch. Sequencing identified 391 variants, which were functionally annotated and ranked based on their predicted clinical impact. Known pathogenic CHEK2 breast cancer variants were identified in five BRCAX families in this study. While BRCAX was an inclusion criterion for this study, we still identified a pathogenic BRCA2 variant (p.Met192ValfsTer13) in one family. A portion of BRCAX families could be explained by other hereditary cancer syndromes that increase HBOC risk: Li-Fraumeni syndrome (gene: TP53) and Lynch syndrome (gene: MSH6). Interestingly, many families carried additional variants of undetermined significance (VOUSs) that may further modify phenotypes of syndromic family members. Ten families carried more than one potential VOUS, suggesting the presence of complex multi-variant families. Overall, nine BRCAX HBOC families in our study may be explained by known likely pathogenic/pathogenic variants, and six families carried potential VOUSs, which require further functional testing. To address this, we developed a functional assay where we successfully re-classified one family’s PMS2 VOUS as benign.
- Published
- 2024
- Full Text
- View/download PDF
33. Educational Video Versus In-person Genetic Counseling for Hereditary Cancer
- Author
-
Yanin Chavarri Guerra, Principal Investigator
- Published
- 2023
34. Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
- Published
- 2023
35. Preimplantation genetic testing for embryos predisposed to hereditary cancer: Possibilities and challenges
- Author
-
Mohammed H. Albujja, Maher Al-Ghedan, Lakshmidevi Dakshnamoorthy, and Josep Pla Victori
- Subjects
Preimplantation genetic testing ,Hereditary cancer ,Late-onset diseases ,Ethics ,Legal restrictions ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Preimplantation genetic testing (PGT), which was developed as an alternative to prenatal genetic testing, allows couples to avoid pregnancies with abnormal chromosomes and the subsequent termination of the affected fetus. Originally used for early onset monogenic conditions, PGT is now used to prevent various types of inherited cancer conditions based on the development of PGT technology, assisted reproductive techniques (ARTs), and in vitro fertilization (IVF). This review provides insights into the potential benefits and challenges associated with the application of PGT for hereditary cancer and provides an overview of the existing literature on this test, with a particular focus on the current challenges related to laws, ethics, counseling, and technology. Additionally, this review predicts the future potential applications of this method. Although PGT may be utilized to predict and prevent hereditary cancer, each case should be comprehensively evaluated. The motives of couples must be assessed to prevent the misuse of this technique for eugenic purposes, and non-pathogenic phenotypes must be carefully evaluated. Pathological cases that require this technology should also be carefully considered based on legal and ethical reasoning. PGT may be the preferred treatment for hereditary cancer cases; however, such cases require careful case-by-case evaluations. Therefore, this study concludes that multidisciplinary counseling and support for patients and their families are essential to ensure that PGT is a viable option that meets all legal and ethical concerns.
- Published
- 2024
- Full Text
- View/download PDF
36. Experiences of patients and family members with follow-up care, information needs and provider support after identification of Lynch Syndrome
- Author
-
Ryan Mooney, Yelena P. Wu, Kelsey Kehoe, Molly Volkmar, Wendy Kohlmann, Cathryn Koptiuch, and Kimberly A Kaphingst
- Subjects
Lynch Syndrome ,Hereditary Cancer ,Patient experiences ,Surveillance ,Screening adherence ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Genetics ,QH426-470 - Abstract
Abstract Background Lynch Syndrome is among the most common hereditary cancer syndromes and requires ongoing cancer surveillance, repeated screenings and potential risk-reducing surgeries. Despite the importance of continued surveillance, there is limited understanding of patient experiences after initial testing and counseling, the barriers or facilitators they experience adhering to recommendations, and how they want to receive information over time. Methods A cross-sectional, observational study was conducted among 127 probands and family members who had received genetic testing for Lynch Syndrome. We conducted semi-structured interviews to determine proband and family member experiences after receiving genetic testing results including their surveillance and screening practices, information needs, and interactions with health care providers. Both closed-ended and open-ended data were collected and analyzed. Results Both probands (96.9%) and family members (76.8%) received recommendations for follow-up screening and all probands (100%) and most family members (98.2%) who tested positive had completed at least one screening. Facilitators to screening included receiving screening procedure reminders and the ease of making screening and surveillance appointments. Insurance coverage to pay for screenings was a frequent concern especially for those under 50 years of age. Participants commented that their primary care providers were often not knowledgeable about Lynch Syndrome and surveillance recommendations; this presented a hardship in navigating ongoing surveillance and updated information. Participants preferred information from a knowledgeable health care provider or a trusted internet source over social media or support groups. Conclusions Probands and family members receiving genetic testing for Lynch Syndrome generally adhered to initial screening and surveillance recommendations. However, factors such as insurance coverage and difficulty finding a knowledgeable healthcare provider presented barriers to receiving recommended follow-up care. There is an opportunity to improve care through better transitions in care, procedures to keep primary care providers informed of surveillance guidelines, and practices so that patients receive reminders and facilitated appointment setting for ongoing screening and surveillance at the time they are due.
- Published
- 2023
- Full Text
- View/download PDF
37. Screening for Mutations in Hereditary Cancer Susceptibility Genes in a Region with High Endogamy in Brazil
- Author
-
Polyanna Oliveira, Paula Correa, Angelina Acosta, Juliana Freitas, Taísa Machado-Lopes, Thais Bomfim-Palma, Ândrea Ribeiro-dos-Santos, Sidney Santos, Roberto Nascimento, Ivana Nascimento, and Kiyoko Abe-Sandes
- Subjects
hereditary cancer ,pathogenic variant ,multigene panel ,endogamy ,Genetics ,QH426-470 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction Cancer is a multifactorial disease dependent on the influence of genetic and environmental factors. About 10% of cancers are associated with germline mutations, which predispose to a higher risk of developing cancer. Currently, the use of panels that identify susceptibility and/or association genes cancer has been increasingly used, both in clinical practice and in scientific research.
- Published
- 2023
- Full Text
- View/download PDF
38. Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
- Author
-
Sokolenko, Anna P., Bakaeva, Elvina Kh., Venina, Aigul R., Kuligina, Ekaterina Sh., Romanko, Alexandr A., Aleksakhina, Svetlana N., Belysheva, Yana V., Belogubova, Evgeniya V., Stepanov, Ilya A., Zaitseva, Olga A., Yatsuk, Olga S., Togo, Alexandr V., Khamgokov, Zaur M., Kadyrova, Azinat O., Pirmagomedov, Albert Sh., Bolieva, Marina B., Epkhiev, Alexandr A., Tsutsaev, Aslan K., Chakhieva, Madina D., and Khabrieva, Khalimat M.
- Abstract
Background: Mountain areas of the North Caucasus host several large ethnic communities that have preserved their national identity over the centuries. Methods: This study involved high-grade serous ovarian cancer (HGSOC) and breast cancer (BC) patients from Dagestan (HGSOC: 37; BC: 198), Kabardino-Balkaria (HGSOC: 68; BC: 155), North Ossetia (HGSOC: 51; BC: 104), Chechnya (HGSOC: 68; BC: 79), Ingushetia (HGSOC: 19; BC: 103), Karachay-Cherkessia (HGSOC: 13; BC: 47), and several Armenian settlements (HGSOC: 16; BC: 101). The group of BC patients was enriched by young-onset and/or family history-positive and/or bilateral and/or receptor triple-negative cases. The entire coding region of BRCA1, BRCA2, PALB2, and ATM genes was analyzed by next-generation sequencing. Results: A significant contribution of BRCA1/2 pathogenic variants (PVs) to HGSOC and BC development was observed across all North Caucasus regions (HGSOC: 19–39%; BC: 6–13%). Founder alleles were identified in all ethnic groups studied, e.g., BRCA1 c.3629_3630delAG in Chechens, BRCA2 c.6341delC in North Ossetians, BRCA2 c.5351dupA in Ingush, and BRCA1 c.2907_2910delTAAA in Karachays. Some BRCA1/2 alleles, particularly BRCA2 c.9895C > T, were shared by several nationalities. ATM PVs were detected in 14 patients, with c.1673delG and c.8876_8879delACTG alleles occurring twice each. PALB2 heterozygosity was observed in 5 subjects, with one variant seen in 2 unrelated women. Conclusion: This study adds to the evidence for the global-wide contribution of BRCA1/2 genes to HGSOC and BC morbidity, although the spectrum of their PVs is a subject of ethnicity-specific variations. The data on founder BRCA1/2 alleles may be considered when adjusting the BRCA1/2 testing procedure to the ethnic origin of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Experiences of patients and family members with follow-up care, information needs and provider support after identification of Lynch Syndrome.
- Author
-
Mooney, Ryan, Wu, Yelena P., Kehoe, Kelsey, Volkmar, Molly, Kohlmann, Wendy, Koptiuch, Cathryn, and Kaphingst, Kimberly A
- Subjects
- *
HEREDITARY nonpolyposis colorectal cancer , *PATIENT experience , *PATIENTS' attitudes , *MEDICAL personnel , *PATIENTS' families , *GENETIC testing - Abstract
Background: Lynch Syndrome is among the most common hereditary cancer syndromes and requires ongoing cancer surveillance, repeated screenings and potential risk-reducing surgeries. Despite the importance of continued surveillance, there is limited understanding of patient experiences after initial testing and counseling, the barriers or facilitators they experience adhering to recommendations, and how they want to receive information over time. Methods: A cross-sectional, observational study was conducted among 127 probands and family members who had received genetic testing for Lynch Syndrome. We conducted semi-structured interviews to determine proband and family member experiences after receiving genetic testing results including their surveillance and screening practices, information needs, and interactions with health care providers. Both closed-ended and open-ended data were collected and analyzed. Results: Both probands (96.9%) and family members (76.8%) received recommendations for follow-up screening and all probands (100%) and most family members (98.2%) who tested positive had completed at least one screening. Facilitators to screening included receiving screening procedure reminders and the ease of making screening and surveillance appointments. Insurance coverage to pay for screenings was a frequent concern especially for those under 50 years of age. Participants commented that their primary care providers were often not knowledgeable about Lynch Syndrome and surveillance recommendations; this presented a hardship in navigating ongoing surveillance and updated information. Participants preferred information from a knowledgeable health care provider or a trusted internet source over social media or support groups. Conclusions: Probands and family members receiving genetic testing for Lynch Syndrome generally adhered to initial screening and surveillance recommendations. However, factors such as insurance coverage and difficulty finding a knowledgeable healthcare provider presented barriers to receiving recommended follow-up care. There is an opportunity to improve care through better transitions in care, procedures to keep primary care providers informed of surveillance guidelines, and practices so that patients receive reminders and facilitated appointment setting for ongoing screening and surveillance at the time they are due. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Detection of Germline Mutations in a Cohort of 250 Relatives of Mutation Carriers in Multigene Panel: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2.
- Author
-
Di Rado, Sara, Giansante, Roberta, Cicirelli, Michela, Pilenzi, Lucrezia, Dell'Elice, Anastasia, Anaclerio, Federico, Rimoldi, Martina, Grassadonia, Antonino, Grossi, Simona, Canale, Nicole, Ballerini, Patrizia, Stuppia, Liborio, and Antonucci, Ivana
- Subjects
- *
GENETIC mutation , *SEQUENCE analysis , *BRCA genes , *RETROSPECTIVE studies , *ACQUISITION of data , *GENETIC disorders , *MEDICAL technology , *GENOMICS , *MEDICAL records , *CARRIER proteins ,TUMOR genetics - Abstract
Simple Summary: During the last few decades, the basis for a genetic predisposition for several cancer syndromes has been clarified, and the highly penetrant/high-risk genes mutated in familial cases are currently subjected to genetic diagnostic screening programs. Mutation testing in these genes has a major impact on genetic counseling, defines the prognosis of carriers, identifies the most appropriate and personalized prophylactic measures, and increases the chance of survival. We aim to underline the effectiveness of the multigene panel in increasing the detection rate of germline mutations in cancer patients and consequently improve the healthy carriers' identification. Background: Several hereditary–familial syndromes associated with various types of tumors have been identified to date, evidencing that hereditary cancers caused by germline mutations account for 5–10% of all tumors. Advances in genetic technology and the implementation of Next-Generation Sequencing (NGS) have accelerated the discovery of several susceptibility cancer genes, allowing for the detection of cancer-predisposing mutations in a larger number of cases. The aim of this study is to highlight how the application of an NGS-multigene panel to a group of oncological patients subsequently leads to improvement in the identification of carriers of healthy pathogenic variants/likely pathogenic variants (PVs/LPVs) and prevention of the disease in these cases. Methods: Starting from a total of 110 cancer patients carrying PVs/LPVs in genes involved in cancer susceptibility detected via a customized NGS panel of 27 cancer-associated genes, we enrolled 250 healthy collateral family members from January 2020 to July 2022. The specific PVs/LPVs identified in each proband were tested in healthy collateral family members via Sanger sequencing. Results: A total of 131 out of the 250 cases (52%) were not carriers of the mutation detected in the affected relative, while 119 were carriers. Of these, 81/250 patients carried PVs/LPVs on BRCA1/2 (33%), 35/250 harbored PVs/LPVs on other genes beyond BRCA1 and BRCA2 (14%), and 3/250 (1%) were PVs/LPVs carriers both on BRCA1/2 and on another susceptibility gene. Conclusion: Our results show that the analysis of BRCA1/2 genes would have only resulted in a missed diagnosis in a number of cases and in the lack of prevention of the disease in a considerable percentage of healthy carriers with a genetic mutation (14%). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Detection Rate and Spectrum of Pathogenic Variations in a Cohort of 83 Patients with Suspected Hereditary Risk of Kidney Cancer.
- Author
-
Ouedraogo, Zangbéwendé Guy, Ceruti, Florian, Lepage, Mathis, Gay-Bellile, Mathilde, Uhrhammer, Nancy, Ponelle-Chachuat, Flora, Bidet, Yannick, Privat, Maud, and Cavaillé, Mathias
- Subjects
- *
RENAL cancer , *DISEASE risk factors , *CANCER genes , *CHECKPOINT kinase 2 , *GENETIC testing , *RECESSIVE genes - Abstract
Hereditary predisposition to cancer affects about 3–5% of renal cancers. Testing criteria have been proposed in France for genetic testing of non-syndromic renal cancer. Our study explores the detection rates associated with our testing criteria. Using a comprehensive gene panel including 8 genes related to renal cancer and 50 genes related to hereditary predisposition to other cancers, we evaluated the detection rate of pathogenic variants in a cohort of 83 patients with suspected renal cancer predisposition. The detection rate was 7.2% for the renal cancer genes, which was 2.41-fold higher than the estimated 3% proportion of unselected kidney cases with inherited risk. Pathogenic variants in renal cancer genes were observed in 44.5% of syndromic cases, and in 2.7% of non-syndromic cases. Incidental findings were observed in CHEK2, MSH2, MUTYH and WRN. CHEK2 was associated with renal cancer (OR at 7.14; 95% CI 1.74–29.6; p < 0.003) in our study in comparison to the gnomAD control population. The detection rate in renal cancer genes was low in non-syndromic cases. Additional causal mechanisms are probably involved, and further research is required to find them. A study of the management of renal cancer risk for CHEK2 pathogenic variant carriers is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. The history of families at-risk for hereditary breast and ovarian cancer: what are the impacts of genetic counseling and testing?
- Author
-
Natalia Campacci, Rebeca Silveira Grasel, Henrique de Campos Reis Galvão, Lucas França Garcia, Paula Carvalho Ribeiro, Kercy Fram de Jesus de Sena Pereira, José Roberto Goldim, Patricia Ashton-Prolla, and Edenir Inêz Palmero
- Subjects
genetics ,hereditary cancer ,genetic counseling ,breast and ovarian cancer predisposition syndrome ,family dynamics ,Psychology ,BF1-990 - Abstract
IntroductionCancer Genetic Counseling (CGC) and genetic testing (GT) assume a paramount role for hereditary cancer predisposition syndrome families. We assessed the effects of CGC and GT on women affected by cancer who are at risk for hereditary breast and ovarian cancer predisposition syndrome (HBOC).MethodsThis study encompasses four time points: before the CGC session, after the CGC session when blood is drawn for GT, after disclosure of GT results, and six months following disclosure of GT results. The impacts of CGC and GT were assessed using psychosocial questionnaires. Additionally, a pedigree, genogram, and ecomap were constructed through a semistructured interview.ResultsA total of sixty women were included in the study. Most participants considered their perception of cancer risk to be equivalent to that of the general population, even among those with pathogenic variants. An increased perception of breast and ovarian cancer risks was associated with a heightened inclination toward religious engagement as a coping mechanism. Patients carrying variants of uncertain significance expressed greater concerns about developing another cancer compared to those who had BRCA1 and BRCA2 wild type or pathogenic variants. Qualitative analysis of the genograms and ecomaps demonstrated that the CGC/GT processes facilitate communication within families. The genogram analyses revealed the impact of CGC and GT processes on families at risk for hereditary cancer. Changes in some family relationships were observed, and an improvement in communication was noted following the GT process.DiscussionThese findings can assist healthcare professionals considering a personalized approaches in clinical practice.
- Published
- 2024
- Full Text
- View/download PDF
43. Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study
- Author
-
Boya Guo, Sarah Knerr, Tia L. Kauffman, Kathleen F. Mittendorf, Erin Keast, Marian J. Gilmore, Heather Spencer Feigelson, Frances L. Lynch, Kristin R. Muessig, Sonia Okuyama, Jamilyn M. Zepp, David L. Veenstra, Li Hsu, Amanda I. Phipps, Sara Lindström, Michael C. Leo, Katrina A. B. Goddard, Benjamin S. Wilfond, Beth Devine, and the CHARM Study team
- Subjects
genetic testing ,genomic sequencing ,health service utilization ,hereditary breast and ovarian cancer ,hereditary cancer ,Lynch syndrome ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Genetic testing can identify cancer risk early, enabling prevention and early detection. We describe use of risk management interventions following genetic testing in the Cancer Health Assessment Reaching Many (CHARM) study. CHARM assessed risk and provided genetic testing to low income, low literacy, and other underserved populations that historically face barriers to accessing cancer genetic services. Methods CHARM was implemented in Kaiser Permanente Northwest (KPNW) and Denver Health (DH) between 2018 and 2020. We identified post‐testing screening (mammography, breast MRI, colonoscopy) and surgical (mastectomy, oophorectomy) procedures using electronic health records. We examined utilization in participants who did and did not receive actionable risk management recommendations from study genetic counselors following national guidelines. Results CHARM participants were followed for an average of 15.4 months (range: 0.4–27.8 months) after results disclosure. Less than 2% (11/680) received actionable risk management recommendations (i.e., could be completed in the initial years following testing) based on their test result. Among those who received actionable recommendations, risk management utilization was moderate (54.5%, 6/11 completed any procedure) and varied by procedure (mammogram: 0/3; MRI: 2/4; colonoscopy: 4/5; mastectomy: 1/5; oophorectomy: 0/3). Cancer screening and surgery procedures were rare in participants without actionable recommendations. Conclusion Though the number of participants who received actionable risk management recommendations was small, our results suggest that implementing CHARM's risk assessment and testing model increased access to evidence‐based genetic services and provided opportunities for patients to engage in recommended preventive care, without encouraging risk management overuse.
- Published
- 2023
- Full Text
- View/download PDF
44. Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing
- Author
-
Deborah Cragun, Gretter Manso, Stefania Alastre Arcusa, Brenda Zuniga, Julie Dutil, Marcia Cruz, and Tuya Pal
- Subjects
hereditary cancer ,genetic counseling ,cancer education ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The delivery of hereditary cancer pre-test education among Spanish-language patients is impeded by the dearth of Spanish-speaking genetic counselors. To address this gap, we evaluated a web-based genetic education tool delivered in Spanish to provide information typically discussed during an initial genetic counseling session. Spanish-speaking patients with a personal or family history of cancer were recruited at two centers in Puerto Rico and through social media. A total of 41 participants completed a survey before and after viewing the tool to measure knowledge, attitudes, and decisional empowerment. A subset of 10 participants completed a virtual semi-structured interview to assess the usability and appropriateness of the tool. Paired t-tests were calculated to evaluate changes in knowledge and attitudes. A McNemar test assessed for decisional empowerment. Interview transcripts were translated from Spanish to English and inductively coded and analyzed. Results revealed significant increases in knowledge (p < 0.001), while attitudes about genetic testing did not change (p = 0.77). The proportion of individuals who felt fully informed and empowered to decide about whether to undergo genetic testing increased from 15% to 51% (p < 0.001). Qualitative data indicated that participants found the tool easy to use with informative and valuable content. Our findings suggest this Spanish-language tool is a user-friendly and scalable solution to help inform and empower many individuals to decide about cancer genetic testing, recognizing that others may still benefit from genetic counseling prior to testing.
- Published
- 2023
- Full Text
- View/download PDF
45. Is There a Role for Risk-Reducing Bilateral Breast Surgery in BRCA1/2 Ovarian Cancer Survivors? An Observational Study
- Author
-
Daniela Oliveira, Sofia Fernandes, Isália Miguel, Sofia Fragoso, and Fátima Vaz
- Subjects
ovarian cancer ,breast cancer ,hereditary cancer ,BRCA ,risk-reducing bilateral breast surgery ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Risk-reducing surgeries are an option for cancer risk management in BRCA1/2 individuals. However, while adnexectomy is commonly recommended in breast cancer (BC) survivors, risk-reducing bilateral breast surgery (RRBBS) is controversial in ovarian cancer (OC) survivors due to relapse rates and mortality. Methods: We conducted a retrospective analysis of BRCA1/2-OC survivors, with OC as first cancer diagnosis. Results: Median age at OC diagnosis for the 69 BRCA1/2-OC survivors was 54 years. Median overall survival was 8 years, being significantly higher for BRCA2 patients than for BRCA1 patients (p = 0.011). Nine patients (13.2%) developed BC at a median age of 61 years. The mean overall BC-free survival was 15.5 years (median not reached). Eight patients (11.8%) underwent bilateral mastectomy (5 simultaneous with BC treatment; 3 RRBBS) at a median age of 56.5 years. The median time from OC to bilateral mastectomy/RRBBS was 5.5 years. Conclusions: This study adds evidence regarding a lower BC risk after BRCA1/2-OC and higher survival for BRCA2-OC patients. A comprehensive analysis of the competing risks of OC mortality and recurrence against the risk of BC should be individually addressed. Surgical BC risk management may be considered for longer BRCA1/2-OC disease-free survivors. Ultimately, these decisions should always be tailored to patients’ characteristics and preferences.
- Published
- 2023
- Full Text
- View/download PDF
46. TP53 p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest Brazil
- Author
-
Tatiana Strava Corrêa, Paula Fontes Asprino, Eduarda Sabá Cordeiro de Oliveira, Ana Carolina Rathsam Leite, Luiza Weis, Maria Isabel Achatz, Claudiner Pereira de Oliveira, Renata Lazari Sandoval, and Romualdo Barroso-Sousa
- Subjects
breast cancer ,hereditary cancer ,Li–Fraumeni syndrome ,TP53 p.R337H ,Genetics ,QH426-470 - Abstract
Despite the high prevalence of TP53 pathogenic variants (PV) carriers in the South and Southeast regions of Brazil, germline genetic testing for hereditary breast cancer (HBC) is not available in the Brazilian public health system, and the prevalence of Li-Fraumeni syndrome (LFS) is not well established in other regions of Brazil. We assessed the occurrence of TP53 p.R337H carriers among women treated for breast cancer (BC) between January 2021 and January 2022 at public hospitals of Brasilia, DF, Brazil. A total of 180 patients who met at least one of the NCCN criteria for HBC underwent germline testing; 44.4% performed out-of-pocket germline multigene panel testing, and 55.6% were tested for the p.R337H variant by allelic discrimination PCR. The median age at BC diagnosis was 43.5 years, 93% had invasive ductal carcinoma, 50% had estrogen receptor-positive/HER2 negative tumors, and 41% and 11% were diagnosed respectively at stage III and IV. Two patients (1.11%) harbored the p.R337H variant, and cascade family testing identified 20 additional carriers. The TP53 p.R337H detection rate was lower than that reported in other studies from south/southeast Brazil. Nonetheless, identifying TP53 PV carriers through genetic testing in the Brazilian public health system could guide cancer treatment and prevention.
- Published
- 2024
- Full Text
- View/download PDF
47. The Crucial Role of Hereditary Cancer Panel Testing in Unaffected Individuals with a Strong Family History of Cancer: A Retrospective Study of a Cohort of 103 Healthy Subjects
- Author
-
Lucrezia Pilenzi, Federico Anaclerio, Anastasia Dell’Elice, Maria Minelli, Roberta Giansante, Michela Cicirelli, Nicola Tinari, Antonino Grassadonia, Andrea Pantalone, Simona Grossi, Nicole Canale, Annalisa Bruno, Giuseppe Calabrese, Patrizia Ballerini, Liborio Stuppia, and Ivana Antonucci
- Subjects
hereditary cancer ,unaffected family member ,NGS multigene panel ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Hereditary cancer syndromes caused by germline mutations account for 5–10% of all cancers. The finding of a genetic mutation could have far-reaching consequences for pharmaceutical therapy, personalized prevention strategies, and cascade testing. According to the National Comprehensive Cancer Network’s (NCCN) and the Italian Association of Medical Oncology (AIOM) guidelines, unaffected family members should be tested only if the affected one is unavailable. This article explores whether germline genetic testing may be offered to high-risk families for hereditary cancer even if a living affected relative is missing. A retrospective study was carried out on 103 healthy subjects tested from 2017 to 2023. We enrolled all subjects with at least two first- or second-degree relatives affected by breast, ovarian, pancreatic, gastric, prostate, or colorectal cancer. All subjects were tested by Next Generation Sequencing (NGS) multi-gene panel of 27 cancer-associated genes. In the study population, 5 (about 5%) pathogenic/likely pathogenic variants (PVs/LPVs) were found, while 40 (42%) had a Variant of Uncertain Significance (VUS). This study highlights the importance of genetic testing for individuals with a strong family history of hereditary malignancies. This approach would allow women who tested positive to receive tailored treatment and prevention strategies based on their personal mutation status.
- Published
- 2024
- Full Text
- View/download PDF
48. Surgery for Medullary Thyroid Cancer
- Author
-
Gréant, E., Shaha, A. R., Nixon, I. J., Mallick, Ujjal K., editor, and Harmer, Clive, editor
- Published
- 2023
- Full Text
- View/download PDF
49. Handling Germline Findings in Ovarian Cancer Cases
- Author
-
Okazawa-Sakai, Mika, Aoki, Daisuke, editor, Nakamura, Seigo, editor, and Miki, Yoshio, editor
- Published
- 2023
- Full Text
- View/download PDF
50. Heterogeneities in Hereditary Cancer Genes as Revealed by a Large-Scale Genome Analysis
- Author
-
Momozawa, Yukihide, Aoki, Daisuke, editor, Nakamura, Seigo, editor, and Miki, Yoshio, editor
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.